Famotidine is a histamine-2 receptor antagonists. Steers received IV famotidine (0.4 mg/kg) as a single and 3-dose regimen (every 8 hours) versus saline control. Abomasal outflow fluid pH was higher in steers treated with famotidine for up to 4 hours after a single dose but the effect decreased with subsequent doses. Famotidine may be useful for treatment or prevention of abomasal ulceration in adult cattle, but the duration of effect may decrease with time[2]. Continued administration of famotidine results in a diminished effect on intragastric pH in dogs[3]. A famotidine CRI (continuous rate infusion), but not standard doses of famotidine, achieves the clinical goals established in people to promote healing of gastric tissue injury and offers an alternative to intravenous treatment with proton pump inhibitors in dogs[4]. Oral famotidine administration results in a diminished effect on intragastric pH in healthy cats when given twice daily every day[5].
Famotidine/法莫替丁 细胞实验
Cell Line
Concentration
Treated Time
Description
References
A549 cells
50 µM
12 hours
Pretreatment of these cells with famotidine reduced TLR3 mRNA levels, but did not affect TLR7 expression.
J Biol Chem. 2021 Aug;297(2):100925.
Caco2 cells
50 µM
12 hours
Famotidine treatment inhibits histamine-induced expression of Toll-like receptor 3 (TLR3) in SARS-CoV-2 infected cells and can reduce TLR3-dependent signaling processes that culminate in activation of IRF3 and the NF-κB pathway, subsequently controlling antiviral and inflammatory responses.
J Biol Chem. 2021 Aug;297(2):100925.
Mouse primary peritoneal macrophages
0 to 30 µM
16 hours
To evaluate the inhibitory effect of famotidine on LPS-induced TNF and IL-6 release, results showed that famotidine did not significantly inhibit LPS-induced TNF and IL-6 release in mouse primary peritoneal macrophages.
Mol Med. 2022 May 16;28(1):57.
RAW 264.7 cells
0 to 30 µM
16 hours
To evaluate the inhibitory effect of famotidine on LPS-induced TNF and IL-6 release, results showed that famotidine did not significantly inhibit LPS-induced TNF and IL-6 release in RAW 264.7 cells.
Mol Med. 2022 May 16;28(1):57.
Human lung A549 cells
up to 200 µM
72 hours
To assess the inhibitory effect of famotidine on SARS-CoV-2 replication in human lung cells, results showed no significant antiviral activity.
Sci Rep. 2021 Mar 8;11(1):5433.
Vero E6 cells
up to 200 µM
72 hours
To evaluate the inhibitory effect of famotidine on SARS-CoV-2 replication, results showed no significant antiviral activity at concentrations up to 200 µM.
Sci Rep. 2021 Mar 8;11(1):5433.
Human lung A549 cells
0.01–200 µM
72 hours
Test the inhibitory effect of ML188 on SARS-CoV-2 replication, results showed no inhibition
Sci Rep. 2021 Mar 8;11(1):5433
Vero E6 cells
0.01–200 µM
72 hours
Test the inhibitory effect of ML188 on SARS-CoV-2 replication, results showed no inhibition
Sci Rep. 2021 Mar 8;11(1):5433
Famotidine/法莫替丁 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
LPS-induced cytokine storm model
Intraperitoneal injection (IP)
0.4 or 4 mg/kg
Single injection or twice daily for 3 days
To evaluate the inhibitory effect of famotidine on LPS-induced cytokine storm, results showed that famotidine significantly reduced serum and splenic TNF and IL-6 levels and improved survival rate.
搜索
